Endocrinology. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze–thaw cycles

By Kol S.  

Human Reproduction, Vol. 14, Iss. 9, 1999-09 ,pp. : 2242-2244

Oxford University Press

Access to resources Recommend Favorite

Case report. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization

By de Jong D  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 573-575

Oxford University Press

Access to resources Recommend Favorite

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?

By Lin Y  

Human Reproduction, Vol. 14, Iss. 4, 1999-04 ,pp. : 885-888

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles

By Albano C.  

Human Reproduction, Vol. 14, Iss. 6, 1999-06 ,pp. : 1426-1430

Oxford University Press

Access to resources Recommend Favorite

Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome

By Elgendy M   Afnan M  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2382-2385

Oxford University Press

Access to resources Recommend Favorite